MDMX exerts its oncogenic activity via suppression of retinoblastoma protein

Oncogene

Volumn 34, Issue 44, 2015, Pages 5560-5569

  Zhang, H ^a   Hu, L ^a   Qiu, W ^b   Deng, T ^a   Zhang, Y ^a   Bergholz, J ^a,c   Xiao, Z X ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RETINOBLASTOMA PROTEIN; MDM2 PROTEIN, HUMAN; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN BINDING; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL AGING; CELL CYCLE ARREST; CONTROLLED STUDY; ENZYME INHIBITION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; GENETICS; HUMAN; NUDE MOUSE; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 84946499653     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.11     Document Type: Article

References (47)

1. Di Fiore R, D'Anneo A, Tesoriere G, Vento R. RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis. J Cell Physiol 2013; 228: 1676-1687.
2. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002; 2: 910-917.
3. Thomas DM, Yang H-S, Alexander K, Hinds PW. Role of the retinoblastoma protein in differentiation and senescence. Cancer Biol Ther 2003; 2: 124-130.
4. Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 2013; 14: 297-306.
5. Lee C, Chang JH, Lee HS, Cho Y. Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor. Genes Dev 2002; 16: 3199-3212.
6. Xiao B, Spencer J, Clements A, Ali-Khan N, Mittnacht S, Broceo C et al. Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation. Proc Natl Acad Sci USA 2003; 100: 2363-2368.
7. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8: 671-682.
8. Henley SA, Dick FA. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div 2012; 7: 10.
9. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 1997; 272: 12738-12746.
10. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98: 859-869.
11. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006; 25: 5220-5227.
12. Avni D, Yang H, Martelli F, Hofmann F, ElShamy WM, Ganesan S et al. Active localization of the retinoblastoma protein in chromatin and its response to S phase DNA damage. Mol Cell 2003; 12: 735-746.
13. Cicchillitti L, Fasanaro P, Biglioli P, Capogrossi MC, Martelli F. Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130. J Biol Chem 2003; 278: 19509-19517.
14. Ludlow JW, Glendening CL, Livingston DM, DeCarprio JA. Specific enzymatic dephosphorylation of the retinoblastoma protein. Mol Cell Biol 1993; 13: 367-372.
15. Marine J-C, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 2010; 17: 93-102.
16. Sdek P, Ying H, Chang DLF, Qiu W, Zheng H, Touitou R et al. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 2005; 20: 699-708.
17. Sdek P, Ying H, Zheng H, Margulis A, Tang X, Tian K et al. The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J Biol Chem 2004; 279: 53317-53322.
18. Wade M, Li Y-C, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13: 83-96.
19. Bottger V, Bottger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG et al. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 1999; 18: 189-199.
20. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J 1996; 15: 5349-5357.
21. Sharp DA, Kratowicz SA, Sank MJ, George DL. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 1999; 274: 38189-38196.
22. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett 1999; 447: 5-9.
23. Kawai H, Lopez-Pajares V, Kim MM, Wiederschain D, Yuan Z-M. RING domainmediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res 2007; 67: 6026-6030.
24. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA 2003; 100: 12009-12014.
25. Okamoto K, Taya Y, Nakagama H. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett 2009; 583: 2710-2714.
26. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL. Structure of the MDM2/ MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 2008; 15: 841-848.
27. Huang L, Yan Z, Liao X, Li Y, Yang J, Wang Z-G et al. The p53 inhibitors MDM2/ MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci USA 2011; 108: 12001-12006.
28. Pant V, Xiong S, Iwakuma T, Quints-Cardama A, Lozano G. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci USA 2011; 108: 11995-12000.
29. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363-9367.
30. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88: 593-602.
31. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 2000; 19: 1473-1476.
32. Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG et al. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem 2002; 277: 19251-19254.
33. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137: 609-622.
34. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003; 15: 164-171.
35. Wu L, Levine AJ. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Molecular medicine 1997; 3: 441-451.
36. Reinke V, Lozano G. Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. Radiation research 1997; 148: 115-122.
37. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 2009; 7: 1-11.
38. Jin Y, Zeng SX, Sun X-X, Lee H, Blattner C, Xiao Z et al. MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2. Mol Cell Biol 2008; 28: 1218-1229.
39. Uchida C, Miwa S, Isobe T, Kitagawa K, Hattori T, Oda T et al. Effects of MdmX on Mdm2-mediated downregulation of pRB. FEBS Lett 2006; 580: 1753-1758.
40. Wunderlich M, Ghosh M, Weghorst K, Berberich SJ. MdmX represses E2F1 transactivation. Cell Cycle 2004; 3: 472-478.
41. Marine J-C, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13: 927-934.
42. Laurie NA, Donovan SL, Shih C-S, Zhang J, Mills N, Fuller C et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444: 61-66.
43. Kato MV, Shimizu T, Ishizaki K, Kaneko A, Yandell DW, Toguchida J et al. Loss of heterozygosity on chromosome 17 and mutation of the p53 gene in retinoblastoma. Cancer Lett 1996; 106: 75-82.
44. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54: 794-799.
45. Suda T, Yoshihara M, Nakamura Y, Sekiguchi H, Godai T-I, Sugano N et al. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable. Oncol Rep 2011; 26: 49-54.
46. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994; 84: 3158-3165.
47. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375: 694-698.